INT47811

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 1995
Last Reported 2004
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 11
Disease Relevance 4.00
Pain Relevance 7.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lyase activity (Ddc) intracellular (Ddc) cellular amino acid metabolic process (Ddc)
cytoplasm (Ddc)
Anatomy Link Frequency
nucleus accumbens 5
neuronal 4
nerve 4
ventral 3
hypothalamic nucleus 2
Ddc (Rattus norvegicus)
Pain Link Frequency Relevance Heat
tetrodotoxin 21 100.00 Very High Very High Very High
Eae 20 100.00 Very High Very High Very High
Neurotransmitter 9 100.00 Very High Very High Very High
antagonist 5 100.00 Very High Very High Very High
Nicotine 24 99.98 Very High Very High Very High
Ventral tegmentum 12 99.98 Very High Very High Very High
medulla 25 99.84 Very High Very High Very High
Nucleus accumbens 20 99.76 Very High Very High Very High
Rostral ventrolateral medulla 30 98.84 Very High Very High Very High
Dopamine 6 94.36 High High
Disease Link Frequency Relevance Heat
Autoimmune Hepatitis 169 99.84 Very High Very High Very High
Hypopigmentation 2 99.52 Very High Very High Very High
Sprains And Strains 5 99.32 Very High Very High Very High
Hypertension 25 99.28 Very High Very High Very High
Disease 37 99.04 Very High Very High Very High
Hepatitis 18 98.96 Very High Very High Very High
Heart Rate Under Development 6 92.80 High High
Ganglion Cysts 4 92.08 High High
INFLAMMATION 4 82.24 Quite High
Pressure Volume 2 Under Development 2 82.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Systemic nicotine (1 mg/kg s.c.) increased locomotor activity and L-DOPA release preferentially in the nucleus accumbens as compared with the striatum.
Positive_regulation (increased) of Localization (release) of L-DOPA in nucleus accumbens associated with nucleus accumbens, eae and nicotine
1) Confidence 0.69 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8874145 Disease Relevance 0 Pain Relevance 0.88
Injection of nicotine (30 micrograms) into the ventral tegmental area increased locomotor activity and L-DOPA release from the nucleus accumbens.
Positive_regulation (increased) of Localization (release) of L-DOPA in nucleus accumbens associated with nucleus accumbens, ventral tegmentum, eae and nicotine
2) Confidence 0.69 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8874145 Disease Relevance 0 Pain Relevance 0.92
Ventral tegmental injection of nicotine induces locomotor activity and L-DOPA release from nucleus accumbens.
Positive_regulation (induces) of in Ventral Localization (release) of L-DOPA in nucleus accumbens associated with nucleus accumbens, eae and nicotine
3) Confidence 0.69 Published 1996 Journal Eur. J. Pharmacol. Section Title Doc Link 8874145 Disease Relevance 0 Pain Relevance 0.88
Intensive electrical stimulation of the ipsilateral posterior hypothalamic nucleus (50 Hz, 0.3 mA, 0.1 ms duration, twice for 5 min at an interval of 5 min) selectively caused the release of L-DOPA in a repetitive and constant manner.
Positive_regulation (caused) of Localization (release) of L-DOPA in hypothalamic nucleus
4) Confidence 0.60 Published 1999 Journal Neuroscience Section Abstract Doc Link 10392836 Disease Relevance 0.35 Pain Relevance 0.74
Nicotine induces locomotor activity and L-DOPA release from the nucleus accumbens via nicotinic receptors in the ventral tegmental area.
Positive_regulation (induces) of Localization (release) of L-DOPA in ventral associated with ventral tegmentum, nucleus accumbens, eae and nicotine
5) Confidence 0.50 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8874145 Disease Relevance 0 Pain Relevance 0.92
By microdialysis in CVLM, basal L-DOPA release was constantly detectable and was lower in SHR than that in WKY.
Positive_regulation (lower) of Localization (release) of L-DOPA in CVLM associated with medulla
6) Confidence 0.43 Published 1995 Journal Neurosci. Lett. Section Abstract Doc Link 8570091 Disease Relevance 0.25 Pain Relevance 0.50
Enhanced presynaptic neuronal L-DOPA release, including a decrease in decarboxylation and sensitization of postsynaptic pressor sites to L-DOPA in RVLM, may be involved in the maintenance of hypertension in SHR.
Positive_regulation (Enhanced) of Localization (release) of L-DOPA in neuronal associated with rostral ventrolateral medulla and hypertension
7) Confidence 0.41 Published 1995 Journal Clin Exp Pharmacol Physiol Suppl Section Abstract Doc Link 9072438 Disease Relevance 0.65 Pain Relevance 0.47
Tonic neuronal L-DOPA release is enhanced in spontaneously hypertensive rats.
Positive_regulation (enhanced) of Localization (release) of L-DOPA in neuronal associated with hypertension
8) Confidence 0.40 Published 1995 Journal Neuroscience Section Abstract Doc Link 7477914 Disease Relevance 1.16 Pain Relevance 0.28
It is highly probable that L-DOPA is a neurotransmitter of the baroreceptor afferents terminating in the NTS, which is based on further findings such as (1) antagonism by a competitive L-DOPA antagonist against depressor responses to aortic nerve stimulation, (2) TTX-sensitive L-DOPA release by aortic nerve stimulation, (3) abolition of baroreceptor-stimulated L-DOPA release by bilateral sino-aortic denervation and (4) decreases in tyrosine hydroxylase (TH)- and L-DOPA-immunoreactivities without modifications of dopamine- and DBH-immunoreactivities in the left NTS and ganglion nodosum 7 days after ipsilateral aortic nerve denervation peripheral to the ganglion.
Positive_regulation (baroreceptor-stimulated) of Localization (release) of L-DOPA in nerve associated with ganglion cysts, tetrodotoxin, dopamine, neurotransmitter and antagonist
9) Confidence 0.28 Published 1995 Journal Neurosci. Res. Section Abstract Doc Link 8532212 Disease Relevance 0.18 Pain Relevance 0.96
It is highly probable that L-DOPA is a neurotransmitter of the baroreceptor afferents terminating in the NTS, which is based on further findings such as (1) antagonism by a competitive L-DOPA antagonist against depressor responses to aortic nerve stimulation, (2) TTX-sensitive L-DOPA release by aortic nerve stimulation, (3) abolition of baroreceptor-stimulated L-DOPA release by bilateral sino-aortic denervation and (4) decreases in tyrosine hydroxylase (TH)- and L-DOPA-immunoreactivities without modifications of dopamine- and DBH-immunoreactivities in the left NTS and ganglion nodosum 7 days after ipsilateral aortic nerve denervation peripheral to the ganglion.
Positive_regulation (baroreceptor-stimulated) of Localization (release) of L-DOPA in nerve associated with ganglion cysts, tetrodotoxin, dopamine, neurotransmitter and antagonist
10) Confidence 0.28 Published 1995 Journal Neurosci. Res. Section Abstract Doc Link 8532212 Disease Relevance 0.18 Pain Relevance 1.05
So far, anti-AADC autoantibodies have only been reported in APECED and their role in AIH and vitiligo as disease components of APECED deserve further investigation.

6.

Positive_regulation (role) of Localization (reported) of anti-AADC associated with autoimmune hepatitis, hypopigmentation and disease
11) Confidence 0.11 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 1.23 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox